Citations

Clear

873 citation(s) found for "Carlson, EE".

Is There an Optimal Location for Tympanostomy Tube Placement?
Marinelli, John P. , Bowe, Sarah N. , Gurgel, Richard Klaus , Carlson, Matthew L.

Mayo Clinic

The Laryngoscope | October 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/lary.70907 | PMID 42838568 Get It

The Metabolic Cost Of Steep Incline Treadmill Walking
Yeo, Dongwook , Carlson, Alex R., Johnston, Jessi I., Ziegler, Briana, Wentz, Robert J., Olson, Lucas A., Hunter Downs, J., Kim, Chul-Ho, Johnson, Bruce D., Carlson, Alex R. , Johnston, Jessica I., Wentz, Robert J., Kim, Chul‐Ho , Johnson, Bruce D.

Mayo Clinic

Medicine & Science in Sports & Exercise | September 18, 2026 | Volume: 58 | Issue: 10S | Pages: No page available

10.1249/01.mss.0001263140.75996.84 Get It

Improved Visualization of Middle Ear Prostheses using Photon-Counting Detector CT: A Cadaver Study
Sadeghian, Maryam, Benson, John C. , Lane, John I. , Treb, Kevin , Khandalavala, Karl R. , Babajanian, Eric E. , Bruesewitz, Michael R. , Swicklik, Joseph R., Ou, Fang‐Shu , McCollough, Cynthia H, Carlson, Matthew L, Leng, Shuai, Ou, Fang-Shu , Sadeghian, Maryam , Farnsworth, Paul J. , McCollough, Cynthia H. , Carlson, Matthew L. , Leng, Shuai , Treb, Kevin J, McCollough, Cynthia H , Leng, Shuai

Mayo Clinic

Radiology Advances | September 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/radadv/umag041 | PMID 42829685 Get It

Abstract Background Evaluation of middle ear prostheses requires high-resolution imaging to assess position and structural integrity. Purpose To assess the diagnostic performance of photon-counting-detector (PCD)-CT for middle ear prosthesis imaging in cadaveric specimens. Materials and Methods Nine different middle ear prostheses were implanted in five fresh-frozen whole-head specimens, both in correct anatomic position and displaced to mimic malposition. Specimens were scanned on PCD-CT (NAEOTOM Alpha, Siemens) and energy-integrating-detector (EID)-CT (SOMATOM Force, Siemens), reconstructed at 0.2mm and 0.4mm, respectively. Eighteen cases (9 prostheses, 2 positions) per scanner were evaluated by two neuroradiologists (36 readings), blinded to scanner and position, who scored prosthesis position, reader confidence, and overall image quality. Agreement with the reference standard and between readers was compared. Results PCD-CT showed higher diagnostic confidence compared with EID-CT, while accuracy and inter-reader agreement did not demonstrate significant differences between scanners. Correct readings, PCD-CT versus EID-CT: lateral contact, 31/36 (86.1%; 95% CI: 58.3%-94.4%) vs. 29/36 (80.6%; 55.6%-91.7%), p = 0.500; medial contact, 30/36 (83.3%; 55.6%-94.4%) vs. 26/36 (72.2%; 50.0%-83.3%), p = 0.250. PCD-CT identified all cases of complete contact loss (score 3), while EID-CT missed one reading per contact. Inter-reader agreement may be higher with PCD-CT vs EID-CT (lateral: κw: 0.804 [0.578-0.941] vs. 0.571 [0.302-0.778], p = 0.250; medial: 0.684 [0.191-0.934] vs. 0.481 [0.024-0.835], p = 0.250). Reader confidence was significantly higher with PCD-CT; mean paired differences for Readers 1 and 2 were 9.4 (1.8-17.1; Holm-adjusted p = 0.019) and 23.1 points (13.4-32.7; p < 0.001) for lateral contact, and 16.4 (10.0-22.8; p < 0.001) and 17.8 points (6.8-28.8; p = 0.007) for medial contact. Readers preferred PCD-CT image quality in 16/18 (88.9%; 65.3%-98.6%) and 17/18 cases (94.4%; 72.7%-99.9%), respectively. Conclusion PCD-CT was associated with significantly higher reader confidence and preferred image quality, without significant differences in diagnostic accuracy or inter-reader agreement. These findings suggest PCD-CT is a promising modality for postoperative middle ear evaluations that warrants further investigations.
Artificial Intelligence‐Estimated Intrapancreatic Fat and Its Relationship to Familial and Germline Pancreatic Cancer Risk
Konikoff, Tom , Takahashi, Hiroaki , Suman, Garima , Mishra, Anup Kumar , Korfiatis, Panos, Carlson, Erin E., Bamlet, William R., Pradeep, Aishwarya , Harper, Kelly, Delgado, Adriana, Goenka, Ajit H. , Oberg, Ann L. , Takahashi, Hiroaki , Nugen, Fred , Mishra, Anup , Pradeep, Aishwarya , Doering, Karen A , Erickson, Bradley J , Goenka, Ajit Harishkumar , Takahashi, Naoki , Oberg, Ann L , Majumder, Shounak , Janssens, Laurens , Nugen, Fred , Carlson, Erin E., Bamlet, William R. , Doering, Karen A. , Delgado, Adriana, Erickson, Bradley J. , Takahashi, Naoki , Majumder, Shounak

Mayo Clinic

United European Gastroenterology Journal | August 29, 2026 | Volume: 14 | Issue: 7 | Pages: No page available

10.1002/ueg2.70279 | PMID 42666046 Get It

ABSTRACT Background Family history of pancreatic cancer (PC), pathogenic germline variants (PGVs), and increased intrapancreatic fat (IPF) are individually associated with increased PC risk. Whether IPF is elevated in high‐risk individuals (HRIs) with PC family history or PGVs is unknown. Although MRI is the preferred modality for IPF measurement, region‐of‐interest–based approaches are prone to sampling bias because pancreatic fat is heterogeneously distributed. We aimed to compare IPF among HRIs and matched non‐HRI controls using an Artificial intelligence (AI)‐based tool for whole pancreatic IPF measurement applied to magnetic resonance imaging (MRI). Methods We developed and validated a deep‐learning pipeline for IPF measurement that incorporates automated pancreas segmentation on T1‐weighted MRI images registered to the corresponding iterative decomposition of water and fat with echo asymmetry and least squares estimation images to compute IPF using proton density fat fraction (PDFF). This pipeline was used to quantify IPF and assess IPF distribution patterns in 85 HRIs and 170 non‐HRIs matched 1:2 for age, sex, BMI, and diabetes status. A surface erosion approach was developed to minimize the impact of peripancreatic fat on IPF measurement. Linear models adjusting for matching variables were used to assess associations. Results Model‐expert agreement for whole‐pancreas PDFF was excellent (intraclass correlation coefficient 0.99; 95% CI, 0.98–0.99 mean absolute error 1.4%). Mean PDFF did not differ between HRIs and controls (25.8% [11.5] vs. 26.9% [11.4]; p = 0.32). PDFF increased with age ( p = 0.015), male sex ( p < 0.001), presence of diabetes ( p = 0.009), BMI ( p < 0.001). IPF distribution patterns did not differ by risk group. Conclusion An AI‐based approach provides accurate, scalable, and objective assessment of IPF quantity and distribution. IPF quantity and spatial distribution do not appear to differ based on germline or familial predisposition to PC.
Authors’ Response to the Letter to the Editor: Proactive Workplace Violence Prevention in Health Care: A Quality Improvement Project
Babin, Melissa M, Carlson, Cory M., Horvath, Paul R, Weiss, Morgan R., Vang, Zong

Mayo Clinic

Journal of Nursing Care Quality | August 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/ncq.0000000000000996 | PMID 42617097 Get It

Combination treatment with RAF/MEK inhibitor avutometinib and FAK inhibitor defactinib in preclinical models of meningioma
Ijad, Nazanin, Yamazawa, Erika , Burgenske, Danielle, Torrini, Consuelo , Carlson, Brett L. , Summers, Elizabeth J, Migliarese, Christian, Marion, Braxton, Zhang, Britney Shela, Sullivan, Emily, Ellington, Claudia, Sasisekharan, Varun, Decker, Paul A, Kosel, Matthew, Eckel‐Passow, Jeanette E. , Galanis, E., Brastianos, Priscilla K, Brastianos, Priscilla K. , Waller, Katie L. , Nayyar, Naema , Burgenske, Danielle M. , Summers, Elizabeth, Marion, Braxton, Decker, Paul A. , Kosel, Matthew , Sarkaria, Jann N. , Wakimoto, Hiroaki , Vaubel, Rachael A. , Brastianos, Priscilla K. , Torrini, Consuelo , Eckel-Passow, Jeanette E , Galanis, Evanthia , Vaubel, Rachael A

Mayo Clinic

Neuro-Oncology Advances | August 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/noajnl/vdag210 | PMID 42825158 Get It

Abstract Background Meningiomas lack effective therapies for recurrent or aggressive disease. NF2 inactivation, commonly in meningioma, may sensitize tumors to FAK inhibition and interact with MAPK signaling. This study investigated the therapeutic activity of defactinib (FAK inhibitor) and avutometinib (RAF/MEK inhibitor) alone and in combination in preclinical meningioma models. Methods MAPK-altered meningioma cell lines, IOMM-Lee (NF2 wild-type, BRAF p.V600E) and CH157-MN (NF2 mutant, NRAS p.Q61K), BenMen-1 (NF2 mutant, MAPK wild-type), and three patient-derived NF2 mutant cell lines were cultured in matrigel and treated with defactinib and avutometinib in 3D cell viability assays. In vivo, flank and intracranial xenograft models of IOMM-Lee and CH157-MN were treated with VS-4718 (FAK inhibitor, superior pharmokinetics in mice), avutometinib, or combination. Tumor growth, survival, and pharmacokinetic/pharmacodynamic properties were assessed. Results In vitro, combination therapy showed synergistic or additive effects in CH157-MN and IOMM-Lee cells, respectively. Defactinib alone demonstrated activity in NF2-mutant patient-derived and BenMen-1 cells, while avutometinib did not. In vivo, avutometinib monotherapy suppressed tumor growth and extended survival in both flank and intracranial xenograft models, with evidence of favorable pharmacokinetic properties and target pathway inhibition in intracranial tumors. Combination therapy provided enhanced and sustained control of flank CH157-MN meningioma compared to avutometinib alone but did not significantly improve survival over avutometinib alone in intracranial models. Conclusions Avutometinib demonstrated robust anti-tumor effects in flank and intracranial models of MAPK-altered meningioma. Combination benefits were context dependent. Defactinib activity in NF2-mutant patient-derived cells without targetable MAPK-kinase alterations highlights the importance of genomic biomarkers to guide personalized strategies.
Siglec-E functions as a brake for intestinal inflammation to protect from colitis-associated cancer 2260102
Maniaci, Brandon, Crotts, Sydney, Friedman, David, Zastrow, Alexi, Rajcula, Matthew, Barnes, Jackson, Carlson, Abigail, Shapiro, Virginia, Crotts, Sydney B. , Zastrow, Alexi, Rajcula, Matthew, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.856 Get It

Abstract Introduction The lifetime risk for colorectal cancer (CRC) in the United States is approximately 4%. Individuals with Inflammatory Bowel Disease, including Ulcerative Colitis and Crohn’s Disease, have a substantially increased risk of developing colorectal cancer. Siglecs (sialic acid immunoglobulin lectin-like proteins) are a family of receptors that regulates the immune response. Siglec-E is a mouse inhibitory receptor that is primarily expressed by innate cells. While others have demonstrated that Siglec-E KO mice reject tumors faster in multiple tumor models, we have found that colorectal cancer is accelerated in Siglec-E KO mice. Here we aim to investigate the role of Siglec-E in immune homeostasis, inflammation and colorectal cancer development. Methods We used two models of colorectal cancer to assess the role of Siglec-E in tumorigenesis: TS4-cre LSL KRASG12D APClox468/wt (TAR mice) and the DSS/AOM model of colitis-associated cancer. Colons were prepared by separating lamina propria (LP) and epithelial (EP) fractions for flow cytometry. 2cm sections were taken from the middle of colons to generate lysates for ELISA. DSS was administered to WT and Siglec-E KO mice to assess the susceptibility to intestinal inflammation. H&E and IHC for PCNA were performed on colonic tissue from experiments. Results We have found that in both the spontaneous and DSS induced models of CRC, Siglec-E KO mice grow more tumors than WT mice. Siglec-E KO mice have an exquisite susceptibility to DSS induced inflammation and reduced number and proportion of neutrophils after treatment. Lastly, we have found that Siglec-E KO mice at baseline have increased VEGF-A in the colon. Conclusion Siglec-E has a critical role in regulating immune homeostasis in the colon. Siglec-E functions as a brake for intestinal inflammation which protects from the development of colorectal cancer. Funding Source This research was funded by NIH grant CA243545-01A1 (VSS), NIH T32 AI170478 (VSS/BM), and and grant R25 GM055252-26 Deans fellowship: Initiative for maximizing student development (IMSD). Topic Categories Cellular Adhesion, Migration, and Inflammation (CAM)
Defining the Role of HDAC3 Enzymatic vs. Adaptor Function in T Cells 2258602
Martinez, Kodi, Shapiro, Michael, Chen, Maggie, Choe, Justin, Crotts, Sydney, Maniaci, Brandon, Zastrow, Alexi, Barnes, Jackson, Carlson, Abby, Shapiro, Virginia, Martinez, Kodi, Shapiro, Michael, Crotts, Sydney B. , Zastrow, Alexi, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.603 Get It

Abstract Introduction Generation of T cells requires dynamic epigenetic alteration of histones to control gene expression at each developmental stage. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) facilitate addition or removal of various acyl groups from lysine residues, including acetylation (KAc) and crotonylation (KCr). The Class I deacetylases HDAC1, HDAC2, and HDAC3 have been shown to have 3 functions: adaptor, decrotonylase, and deacetylase activity. The relative importance of each function in T cells is not known. Genetic knockout of HDAC3 in mice using CD2icre results in a severe block in T cell development and spontaneous development of severe colitis. Our lab determined that HDAC3 is required for three different aspects of this process: CD4+CD8 + (DP) cell survival, positive selection, and CD4+ lineage commitment. We generated a novel mouse model with CD2icre-mediated deletion of endogenous HDAC3 and linked re-expression of HDAC3 “VRPP” mutant mice, which maintained adaptor function but lacks enzymatic activity. Strikingly, these mice do not develop spontaneous colitis even up to one year of age. Methods We used flow cytometry to assess T cell development and maturation in the thymus, spleen, mLN, and colon of HDAC3 cKO vs. HDAC3 VRPP mice. CUT&RUN was utilized to determine differences in H3K9Ac, H3K27Ac, and H3K18Cr across CD8 and CD4 lineage genes. H&E was utilized to assess structural changes in thymus and colon. Results Similar to CD2icre HDAC3 cKO mice, HDAC3 VRPP mice have a block in positive selection due to failure to down regulate RORγt and decreased DP cell survival due to increased expression of P2RX7. Although fewer T cells are produced in HDAC3 VRPP mice, CD4+ lineage commitment is restored, likely mitigating the development of spontaneous colitis. Conclusion Our results demonstrate that HDAC3 enzymatic activity is necessary for several aspects of T cell development, while HDAC3 adaptor function is sufficient to restore CD4+ lineage commitment. Funding Source NIAID RO1 AI150100, T32 AI170478 Topic Categories Hematopoiesis and Immune System Development (HEM)
Tregs Require ABCB7 for their Development and Stability 2258259
Zastrow, Alexi, Zhao, Geoffrey , Kim, Eugene, Lehrke, Michael, Rajcula, Matt, Chen, Maggie , Crotts, Sydney, Maniaci, Brandon, Martinez, Kodi, Barnes, Jackson, Carlson, Abigail, Zastrow, Alexi, Lehrke, Michael Jonathan , Rajcula, Matthew, Crotts, Sydney B. , Martinez, Kodi, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.565 Get It

Abstract Introduction The mitochondrial transporter ABCB7 is essential for exporting iron-sulfur (Fe-S) clusters, a function known to be critical in B cells. This study was conducted to investigate the broader, previously unknown roles of ABCB7 in regulating the overall lymphocyte development and homeostasis. Methods The study utilized conditional knockout (cKO) mouse models (CD2-iCre and Mb1-Cre) to create a specific deficiency of ABCB7 in certain immune populations. To determine if the observed effects were due to ABCB7 deletion in myeloid cells, two further models (CD2i-Cre ABCB7 cKO/C/EBPα and CD2-iCre LSL TMT ABCB7 cKO) were developed. The effects of blocking the cytokine G-CSF were also examined to understand its role in the observed myelopoiesis. Results ABCB7 deficiency was found to dramatically impair erythropoiesis while simultaneously driving emergency myelopoiesis. We confirmed that the myeloid expansion was not a direct result of ABCB7 loss in myeloid cells. A significant autoimmune phenotype also developed, characterized by hyperactivated T cells and a sharp decrease in peripheral regulatory T cells (Tregs). This Treg instability was linked to decreased thymic expression of key stability genes (like CD28 and PD-1) and reduced O-GlcNAc modification in T cells, a process crucial for maintaining Treg lineage. Conclusion The findings establish ABCB7 as a pivotal regulator of hematopoietic balance, linking mitochondrial function to both myeloid expansion and Treg stability. Funding Source T32AI170478 Topic Categories Hematopoiesis and Immune System Development (HEM)